Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280747 | 0.71 | KDM4E (0.45) | APEX1AKR1B10AKR1B1KMT2A | |
| SCHEMBL11711947 | 0.68 | KDM4E (0.47) | APEX1AKR1B10AKR1B1KMT2A | |
| SCHEMBL5479277 | 0.66 | CYP2D6 (0.35) | AKR1B10AKR1B1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL677187 | 0.65 | APEX1 (0.62) | APEX1MEN1KMT2A | |
| SCHEMBL7567713 | 0.64 | ALDH1A1 (0.44) | APEX1AKR1B10AKR1B1MEN1KMT2A | |
| SCHEMBL21062093 | 0.63 | KMT2A (0.42) | APEX1AKR1B10AKR1B1MEN1KMT2A | |
| SCHEMBL3785483 | 0.63 | MAPK8 (0.45) | APEX1HSD17B10MEN1KMT2A | |
| SCHEMBL11842214 | 0.63 | APEX1 (0.50) | APEX1AKR1B1ALOX15HSD17B10MEN1 | |
| SCHEMBL11808900 | 0.62 | APEX1 (1.00) | APEX1MEN1KMT2A | |
| SCHEMBL22092291 | 0.62 | APEX1 (0.48) | APEX1AKR1B1ALOX15HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171764-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | ABBOTT MOLECULAR INC. | 2025-05-29 | — | — | US | disclosed |
| US-20230193240-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | ABBOTT MOLECULAR INC. | 2023-06-22 | — | — | US | disclosed |
| US-11608496-B2 | Purification of nucleic acids using copper-titanium oxides | ABBOTT MOLECULAR INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3988658-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | Abbott Molecular Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11313001-B2 | Compositions and methods for detection of microorganisms | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-11225693-B2 | Compositions and methods for identifying drug resistant tuberculosis | ABBOTT MOLECULAR INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11214603-B2 | C3D cellular and acellular vaccines for the prevention and treatment of cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3322805-B1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES OR MAGNESIUM-TITANIUM OXIDES | ABBOTT MOLECULAR INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210222153-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | ABBOTT MOLECULAR INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210180117-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF MICROORGANISMS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-06-17 | — | — | US | disclosed |
| WO-2009155093-A2 | COMPOSITIONS FOR USE IN IDENTIFICATION OF ENTERIC BACTERIAL PATHOGENS | IBIS BIOSCIENCES, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009151982-A1 | COMPOSITIONS FOR USE IN IDENTIFICATION OF FRANCISELLA | IBIS BIOSCIENCES, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009131728-A2 | COMPOSITIONS FOR USE IN IDENTIFICATION OF PICORNAVIRUSES | IBIS BIOSCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090092982-A1 | METHODS AND COMPOSITIONS FOR INCREASING BIOLOGICAL MOLECULE STABILITY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009032664-A2 | METHODS AND COMPOSITIONS FOR INCREASING BIOLOGICAL MOLECULE STABILITY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2007133250-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER | GURNEY AUSTIN (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1599164-A4 | METHODS FOR TREATING, PREVENTING AND DETECTING HELICOBACTER INFECTION | CEREBUS BIOLOG INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070117751-A1 | Frizzled receptor specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative disorders | MEREO BIOPHARMA 5, INC. | 2007-05-24 | — | — | US | disclosed |
| EP-1599164-A2 | METHODS FOR TREATING, PREVENTING AND DETECTING HELICOBACTER INFECTION | Cerebus Biologicals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004069184-A2 | METHODS FOR TREATING, PREVENTING AND DETECTING HELICOBACTER INFECTION | CEREBUS BIOLOGICALS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |